M&A / Deals RA Capital targets China with latest SPAC deal BioPharma DiveThe prominent investor aims to merge its latest special purpose acquisition company with a Chinese biotech, according to a securities filing.M&A / DealsRead full story pharminent March 24, 2026 (Last updated: March 25, 2026) BioPharma Dive The prominent investor aims to merge its latest special purpose acquisition company with a Chinese biotech, according to a securities filing. M&A / DealsRead full story Post navigation Previous: Immutrin raises $87M to advance drug for progressive heart diseaseNext: Gilead, with Ouro deal, wagers $1.7B on bispecifics for autoimmune diseases Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026